Related Experiment Video
Updated: Jun 21, 2025

Differentiation of Mouse Breast Epithelial HC11 and EpH4 Cells
Published on: February 27, 2020
The LDHC-STAT3 Signaling Network Is a Key Regulator of Basal-like Breast Cancer Cell Survival
Adviti Naik1, Remy Thomas1, Martin Sikhondze1
1Cancer Research Center, Qatar Biomedical Research Institute (QBRI), Hamad Bin Khalifa University (HBKU), Qatar Foundation (QF), Doha P.O. Box 34110, Qatar.
Abstract:
Breast cancer treatment has evolved drastically with the addition of immunotherapy and novel targeted drugs to the current treatment options. However, achieving long-term responses with minimal adverse events remains challenging. Cancer testis antigens (CTAs) offer novel opportunities for drug development thanks to their tumor specificity, immunogenicity, pro-tumorigenic functions, and negative prognostic connotations. We previously reported that lactate dehydrogenase C (LDHC) plays a key role in regulating genomic stability and that targeting LDHC significantly improved treatment response to DNA damage response drugs in breast cancer. Here, we explored the molecular mechanisms associated with LDHC silencing in two basal-like breast cancer cell lines, MDA-MB-468 and BT-549, and a Her2-enriched breast cancer cell line, HCC-1954. Transcriptomic analyses identified the cell line-dependent differential activation of the pro-survival STAT3 pathway following LDHC depletion. While LDHC silencing significantly compromised cell survival in basal-like breast cancer cells in conjunction with a downregulation of STAT3 signaling, the opposite effect was observed in Her2-enriched breast cancer cells, which demonstrated the enhanced activation of the pro-survival STAT3 signaling pathway. The inhibition of STAT3 not only reversed the unfavorable effect of LDHC silencing in the Her2-enriched cancer cells but also demonstrated significant anti-cancer activity when used as a single agent. Our findings suggest that the LDHC-STAT3 signaling axis plays a role in regulating breast tumor cell survival in a subtype-dependent manner. Thus, LDHC-targeted therapy could be a viable therapeutic approach for a subset of breast cancer patients, particularly patients with basal-like breast cancer, whereas patients carrying Her2-enriched tumors may likely benefit more from monotherapy with STAT3 inhibitors.
Insights
Targeting lactate dehydrogenase C (LDHC) impacts breast cancer cell survival differently based on subtype. LDHC silencing harms basal-like breast cancer but aids Her2-enriched tumors, suggesting subtype-specific therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Breast cancer treatment advances include immunotherapy and targeted drugs, yet long-term efficacy with minimal side effects remains a challenge.
- Cancer testis antigens (CTAs) present therapeutic opportunities due to tumor specificity and immunogenicity.
- Lactate dehydrogenase C (LDHC) is implicated in genomic stability, and its targeting enhances responses to DNA damage response drugs in breast cancer.
Purpose of the Study:
- To investigate the molecular mechanisms of LDHC silencing in different breast cancer subtypes.
- To explore the role of the LDHC-STAT3 signaling axis in breast tumor cell survival.
- To determine the potential of LDHC-targeted therapy and STAT3 inhibition for specific breast cancer subtypes.
Main Methods:
- LDHC silencing was performed in basal-like (MDA-MB-468, BT-549) and Her2-enriched (HCC-1954) breast cancer cell lines.
- Transcriptomic analyses were conducted to assess gene expression changes and pathway activation.
- STAT3 signaling pathway activity was evaluated following LDHC depletion, with and without STAT3 inhibition.
Main Results:
- LDHC silencing differentially affected STAT3 pathway activation in a cell line-dependent manner.
- In basal-like breast cancer cells, LDHC silencing compromised survival and downregulated STAT3 signaling.
- In Her2-enriched breast cancer cells, LDHC silencing enhanced STAT3 signaling and cell survival; STAT3 inhibition reversed this effect and showed single-agent anti-cancer activity.
Conclusions:
- The LDHC-STAT3 signaling axis regulates breast tumor cell survival in a subtype-specific manner.
- LDHC-targeted therapy may benefit basal-like breast cancer patients.
- Her2-enriched breast cancer patients might benefit more from monotherapy with STAT3 inhibitors.
Related Concept Videos
Hedgehog Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Regulation of Angiogenesis and Blood Supply
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The JAK-STAT Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway

